Overview
RIC biologics offers all-round analytical services for pharma and biotech companies working on biological products and chemical entities. The company supports customers across lead selection, formulation, identification, characterization, quantification, stability, and comparability testing. They work with monoclonal antibodies, antibody fragments, antibody-drug-conjugates, bi-specifics, fusion proteins, enzymes, peptides, oligonucleotides, DNA, RNA, and small molecules.
Key people
In the news
- A crossword puzzle, that’s how I’ve been thinking about our mRNA project the moment it stranded (pun intended 🤓 ) in our innovation department. The challenge: cover as much of a therapeutic mRNA sequence as possible using mass spectrometry, so we can find modifications that next-generation sequencing cannot see. Our ultimate solution, it turns out, involves two sets of clues: RNase 4 for the long ‘across’ fragments and RNase A for the short ‘down’ sub-fragments. Helena, Jelle, Evert, Pat, Koen, and I went to work. We built a
- What if you could read your mRNA sequence by solving it crossword style? That’s the idea behind our latest publication in the Journal of Chromatography A. We developed a complementary LC-MS platform for mRNA mapping that combines two ribonucleases (RNase 4 for pre-column digestion and RNase A in a custom post-column cartridge) to generate nested, overlapping sequence information at the full-MS level. Why does this matter? ▪️ Sequence confirmation is a regulatory requirement for therapeutic mRNA ▪️ Next-generation sequencing is not
- This is what Evert’s work in the lab delivers when everything finally clicks (or rather sticks). The question he set out to answer sounds simple: when an antibody loses potency, why? Standard assays can tell you that binding has changed, but not which tiny structural tweak is to blame. So, he built miniaturized HER2 affinity columns and coupled them to multidimensional LC-MS, separating trastuzumab variants by how they actually bind. The answer came back clean: isomerization of heavy-chain Asp102 is what drives the affinity
Something wrong or missing? Send an update. Fixed within 24 hours.